The Michael J. Fox Foundation funds work with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care.
The Therapeutic Pipeline Program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from other disease indications. The Therapeutic Pipeline Program advances Parkinson's disease therapeutic and intervention development along the pre-clinical and clinical path.
This program is part of our Edmond J. Safra Core Programs for PD Research.
Therapies aiming to address one of the following treatment challenges:
- Protection or restoration of degenerating and/or dysfunctional neurons affected in Parkinson’s
- Alleviation of disabling motor or non-motor symptoms of Parkinson’s not well managed by current treatments
- Reduction of complications and side effects of current Parkinson’s treatments.
Pharmacological interventions as well as biologic, gene therapy, surgical and non-invasive/non-pharmaceutical approaches were appropriate. MJFF was particularly interested in efforts focused on developing therapeutics that alleviate non-motor symptoms and on developing telehealth-based therapeutic interventions that alleviate motor and/or non-motor symptoms.
Contact email@example.com with questions about this program or our policies.